Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

This Phase I interventional trial (n=100) aims to evaluate ketamine (KET)-induced gamma potentiation as a prognostic marker for treatment outcomes in patients with treatment-resistant depression (TRD).

Conducted by Baylor College of Medicine and funded by the National Institute of Mental Health (NIMH), the study is set in Houston, Texas.

It will investigate the relationship between gamma band potentiation (GBP) measured by electroencephalogram (EEG) and the antidepressant efficacy of ketamine over a 4-week treatment period. Participants will receive either ketamine or saline infusions to determine how GBP correlates with symptom reduction in TRD.

The study seeks to enhance the understanding of gamma dynamics as a potential marker for predicting treatment response and guiding future research on neuromodulatory therapies for depression.

The trial began in January 2024 and is expected to conclude by December 2025.

Topic Depression Treatment-Resistant Depression
Compound Ketamine Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Baylor College of Medicine
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.